Arcturus Therapeutics Holdings Inc. $ARCT Shares Bought by Jacobs Levy Equity Management Inc.

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in Arcturus Therapeutics by 20.6% in the first quarter, holding 144,141 shares valued at approximately $1.53 million.
• Arcturus Therapeutics reports a negative EPS of ($0.34) for the last quarter, surpassing consensus estimates, alongside a revenue of $28.30 million.
• Eight equities research analysts have rated Arcturus Therapeutics with a "Buy" rating, assigning a consensus price target of $50.57.

Jacobs Levy Equity Management Inc. raised its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 20.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 144,141 shares of the biotechnology company's stock after acquiring an additional 24,583 shares during the period. Jacobs Levy Equity Management Inc. owned 0.53% of Arcturus Therapeutics worth $1,526,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Invesco Ltd. boosted its position in shares of Arcturus Therapeutics by 83.1% during the first quarter. Invesco Ltd. now owns 34,896 shares of the biotechnology company's stock worth $370,000 after buying an additional 15,836 shares during the period. Deutsche Bank AG boosted its position in shares of Arcturus Therapeutics by 42.7% during the fourth quarter. Deutsche Bank AG now owns 24,768 shares of the biotechnology company's stock worth $420,000 after buying an additional 7,417 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Arcturus Therapeutics during the first quarter worth approximately $244,000. GAMMA Investing LLC boosted its position in shares of Arcturus Therapeutics by 3,482.9% during the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock worth $550,000 after buying an additional 5,085 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of Arcturus Therapeutics by 5.0% during the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock worth $316,000 after buying an additional 883 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ARCT shares. HC Wainwright started coverage on Arcturus Therapeutics in a research report on Thursday, September 4th. They set a "buy" rating and a $60.00 price objective for the company. Scotiabank reiterated an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Wall Street Zen raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Citigroup restated a "buy" rating and issued a $49.00 target price (up from $47.00) on shares of Arcturus Therapeutics in a research report on Tuesday, August 12th. Finally, Leerink Partners cut their target price on Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating for the company in a research report on Friday, August 22nd. Eight investment analysts have rated the stock with a Buy rating, According to MarketBeat, Arcturus Therapeutics currently has an average rating of "Buy" and an average price target of $50.57.

Arcturus Therapeutics Stock Down 0.2%

ARCT traded down $0.04 during trading on Tuesday, reaching $18.09. The stock had a trading volume of 927,027 shares, compared to its average volume of 466,978. The firm has a market capitalization of $491.32 million, a price-to-earnings ratio of -8.11 and a beta of 2.39. Arcturus Therapeutics Holdings Inc. has a 1-year low of $8.04 and a 1-year high of $25.88. The stock has a 50 day moving average of $15.56 and a two-hundred day moving average of $13.42.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($1.11) by $0.77. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.The company had revenue of $28.30 million during the quarter, compared to the consensus estimate of $17.64 million. On average, research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.